NCT04201145 2020-11-17Pembrolizumab + Defactinib In Pleural MesotheliomaDana-Farber Cancer InstitutePhase 1 Withdrawn
NCT02758587 2018-03-19Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)NHS Greater Glasgow and ClydePhase 1/2 Unknown59 enrolled